---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019019"
form_type: "8-K"
ticker: "CAPR"
cik: "0001133869"
company_name: "CAPRICOR THERAPEUTICS, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:12:31.209154+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Capricor completes HOPE-3 enrollment; Q3 net loss $6.4M, cash $28.5M

## Summary
- Completed targeted enrollment for HOPE-3 Phase 3 trial of CAP-1002 in Duchenne muscular dystrophy; interim futility analysis expected Q4 2023.
- FDA affirmed alignment on HOPE-3 design; BLA submission planned supported by Cohort A results.
- Q3 revenue $6.2M (from Nippon Shinyaku upfront recognition) vs $1.6M prior year; net loss $6.4M flat YoY.
- Cash $28.5M at Sept 30; subsequent $23M registered direct offering with Nippon Shinyaku extends runway into 2025.
- Appointed Michael Kelliher (Amgen/Horizon) to Board of Directors; advancing StealthX exosome platform.

## SEC filing metadata
- accession: 0001558370-23-019019
- form_type: 8-K
- ticker: CAPR
- cik: 0001133869
- company_name: CAPRICOR THERAPEUTICS, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/0001558370-23-019019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/capr-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019019
- JSON: https://secwatch.observer/filing/0001558370-23-019019.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019019.txt

## Key facts
- Earnings Releases
  CAPRICOR THERAPEUTICS, INC. reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133869/000155837023019019/0001558370-23-019019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.